Biomea Fusion to report Phase I findings for oral GLP-1 drug
Biomea Fusion will release Phase I GLP-131 results for BMF-650 on October 13 and hold an investor conference call and webcast to discuss the data.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
GlobeNewswire reports that Biomea Fusion will announce results on October 13, 2026, from the Phase I GLP-131 clinical study of BMF-650. The company describes BMF-650 as an investigational next-generation oral small-molecule GLP-1 receptor agonist.
Management will discuss the findings during a conference call and webcast beginning at 4:30 p.m. ET, or 1:30 p.m. PT, on October 13. The live event will be available through the Investors and Media section of Biomea Fusion’s website, with a replay to follow online.
Biomea Fusion is a clinical-stage biopharmaceutical company developing the oral small-molecule therapies icovamenib and BMF-650 for diabetes and obesity. Investor relations contact: Meichiel Jennifer Weiss, ir@biomeafusion.com.
why it matters
The Phase I update is the next scheduled data event for BMF-650 and will give the market an initial look at clinical results for Biomea Fusion’s oral metabolic-disease program.
instruments
sources
- Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist — globenewswire.com, 12 October 2026 at 20:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗